Cover Image
市場調查報告書

癲癇治療藥的全球市場:2018年∼2022年

Global Epilepsy Drugs Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 363152
出版日期 內容資訊 英文 112 Pages
訂單完成後即時交付
價格
Back to Top
癲癇治療藥的全球市場:2018年∼2022年 Global Epilepsy Drugs Market 2018-2022
出版日期: 2018年09月25日 內容資訊: 英文 112 Pages
簡介

關於癲癇治療藥

癲癇,特徵是異常的神經原放電增加的神經學性障礙,一時產生感覺/運動神經功能障礙或精神功能障礙的發作。

Technavio的分析師預測,全球癲癇治療藥市場將以從2018年到2022年之間,7.19%的年複合成長率成長。

本報告提供全球癲癇治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 市場情形

  • 市場生態系統
  • 市場特性
  • 市場區隔分析

第5章 開發平台分析

  • 可利用的AED的未滿足需求
  • 癲癇的開發平台藥物

第6章 市場規模

  • 市場定義

第7章 市場規模

  • 市場定義
  • 市場規模及預測(2017-2022年)

第8章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情形

第9章 市場區隔:托曳活動頻譜

  • 市場區隔:各藥物活性頻譜(2017-2022年)
  • 各藥物活性頻譜比較
  • 窄的頻譜的藥物
  • 寬廣的頻譜的藥物
  • 市場機會:各藥物活動頻譜

第10章 市場區隔:各病因

  • 市場區隔:各病因

第11章 市場區隔:各發病年齡

  • 市場區隔:各發病年齡

第12章 客戶形勢

第13章 地區形勢

  • 各地區市場區隔(2017-2022年)
  • 地區比較
  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區
  • 市場機會

第14章 決策架構

第15章 成長要素與課題

  • 市場成長要素
  • 市場課題

第16章 市場趨勢

  • 癲癇管理成本的增加
  • 免疫療法及免疫調節劑的使用
  • 治療方法及診斷法的遺傳學的使用
  • 精密醫療保健基礎設施的研究

第17章 業者情勢

  • 概要
  • 創造性破壞狀況

第18章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Eisai
  • GlaxoSmithKline
  • Novartis
  • Pfizer

第19章 附錄

  • 簡稱的清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR21967

About Epilepsy Drugs

Epilepsy is a neurological disorder characterized by episodes of abnormally increased neuronal discharge resulting in transient episodes of sensory or motor neurological dysfunction or psychic dysfunction.

Technavio's analysts forecast the Global Epilepsy Drugs Market to grow at a CAGR of 7.19% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the epilepsy drugs market. To calculate the market size, the report considers the revenue generated by sales of epilepsy drugs across the globe.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Epilepsy Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Eisai
  • GlaxoSmithKline
  • Novartis
  • Pfizer

Market driver

  • Advances in understanding of epilepsy pathology
  • For a full, detailed list, view our report

Market challenge

  • Low safety profile of AEDs
  • For a full, detailed list, view our report

Market trend

  • Increasing costs of epilepsy management
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Unmet needs of available AEDs
  • Pipeline drugs for epilepsy

PART 06: MARKET SIZING

  • Market definition

PART 07: MARKET SIZING 2017

  • Market definition
  • Market size and forecast 2017-2022

PART 08: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 09: MARKET SEGMENTATION BY DRUG ACTIVITY SPECTRUM

  • Segmentation by drug activity spectrum
  • Comparison by drug activity spectrum
  • Narrow spectrum drugs - Market size and forecast 2017-2022
  • Broad spectrum drugs - Market size and forecast 2017-2022
  • Market opportunity by drug activity spectrum

PART 10: MARKET SEGMENTATION BY ETIOLOGY

  • Segmentation by etiology

PART 11: MARKET SEGMENTATION BY AGE OF ONSET

  • Segmentation by age of onset

PART 12: CUSTOMER LANDSCAPE

PART 13: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 14: DECISION FRAMEWORK

PART 15: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 16: MARKET TRENDS

  • Increase in epilepsy management costs
  • Use of immunotherapy and immunomodulators
  • Use of genetics as therapeutics and diagnostic modality
  • Research in precision healthcare infrastructure

PART 17: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 18: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eisai
  • GlaxoSmithKline
  • Novartis
  • Pfizer

PART 19: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global CNS disorders therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Need, demand, and supply analysis of AEDs
  • Exhibit 06: Pipeline drugs under phase III development
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2017
  • Exhibit 09: Validation techniques employed for market sizing 2017
  • Exhibit 10: Global epilepsy drugs market - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 11: Global epilepsy drugs market - Year over year growth 2018-2022 (%)
  • Exhibit 12: Five forces analysis 2017
  • Exhibit 13: Five forces analysis 2022
  • Exhibit 14: Bargaining power of buyers
  • Exhibit 15: Bargaining power of suppliers
  • Exhibit 16: Threat of new entrants
  • Exhibit 17: Threat of substitutes
  • Exhibit 18: Threat of rivalry
  • Exhibit 19: Market condition - Five forces 2017
  • Exhibit 20: Global epilepsy drugs market by drug activity spectrum - Market share 2017-2022 (%)
  • Exhibit 21: Comparison by drug activity spectrum
  • Exhibit 22: Global epilepsy drugs market by narrow spectrum drugs - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 23: Global epilepsy drugs market by narrow spectrum drugs - Year over year growth 2018-2022 (%)
  • Exhibit 24: Global epilepsy drugs market by broad spectrum drugs - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 25: Global epilepsy drugs market by broad spectrum drugs - Year over year growth 2018-2022 (%)
  • Exhibit 26: Market opportunity by drug activity spectrum
  • Exhibit 27: Customer Landscape
  • Exhibit 28: Global epilepsy drugs market by region - Market share 2017-2022 (%)
  • Exhibit 29: Regional comparison
  • Exhibit 30: Epilepsy drugs market in Americas - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 31: Epilepsy drugs market in Americas - Year over year growth 2018-2022 (%)
  • Exhibit 32: Top three countries in Americas
  • Exhibit 33: Epilepsy drugs market in EMEA - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 34: Epilepsy drugs market in EMEA - Year over year growth 2018-2022 (%)
  • Exhibit 35: Top three countries in EMEA
  • Exhibit 36: Epilepsy drugs market in APAC - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 37: Epilepsy drugs market in APAC - Year over year growth 2018-2022 (%)
  • Exhibit 38: Top three countries in APAC
  • Exhibit 39: Market opportunity
  • Exhibit 40: Examples of epilepsy drugs discontinued due to safety issues:
  • Exhibit 41: Epilepsy management costs
  • Exhibit 42: Price of leading branded AEDs
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Eisai overview
  • Exhibit 49: Eisai - Business segments
  • Exhibit 50: Eisai - Organizational developments
  • Exhibit 51: Eisai - Geographic focus
  • Exhibit 52: Eisai - Segment focus
  • Exhibit 53: Eisai - Key offerings
  • Exhibit 54: GlaxoSmithKline overview
  • Exhibit 55: GlaxoSmithKline - Business segments
  • Exhibit 56: GlaxoSmithKline - Organizational developments
  • Exhibit 57: GlaxoSmithKline - Geographic focus
  • Exhibit 58: GlaxoSmithKline - Segment focus
  • Exhibit 59: GlaxoSmithKline - Key offerings
  • Exhibit 60: Novartis overview
  • Exhibit 61: Novartis - Business segments
  • Exhibit 62: Novartis - Organizational developments
  • Exhibit 63: Novartis - Geographic focus
  • Exhibit 64: Novartis - Segment focus
  • Exhibit 65: Novartis - Key offerings
  • Exhibit 66: Pfizer overview
  • Exhibit 67: Pfizer - Business segments
  • Exhibit 68: Pfizer - Organizational developments
  • Exhibit 69: Pfizer - Geographic focus
  • Exhibit 70: Pfizer - Segment focus
  • Exhibit 71: Pfizer - Key offerings
Back to Top